{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-24-002520","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.905718+00:00","generated_at":"2026-05-31T10:24:03.366923+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entera Bio Q2 2024 net loss $2.1M; cash runway into Q3 2025; EB613 milestone expected","bullets":["Net loss of $2.1M ($0.06 per share) vs $2.3M ($0.08) in Q2 2023; cash $9.1M at June 30, 2024.","R&D expenses $1.1M (down $0.1M YoY); G&A flat at $1.1M; operating expenses $2.2M.","EB613 (oral PTH) Phase 2 data published in JBMR; FDA SABRE endpoint ruling expected ~5 months.","EB612 hypoparathyroidism Phase 1 data at ENDO 2024; potential move to Phase 2 soon.","Collaboration with OPKO on oral GLP-2 (short bowel) and GLP-1/glucagon (obesity) ongoing; PK data due H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-24-002520","json":"https://secwatch.observer/filing/0001178913-24-002520.json","markdown":"https://secwatch.observer/filing/0001178913-24-002520.md","text":"https://secwatch.observer/filing/0001178913-24-002520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324002520/0001178913-24-002520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324002520/zk2431821.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:24:03.366923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}